Canada Breast Cancer Therapeutics Market By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others), By Region, Competition Forecast and Opportunities, 2018-2028
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCanada Breast Cancer Therapeutics Market By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others), By Region, Competition Forecast and Opportunities, 2018-2028
For instance, in 2020, about 27,400 women were diagnosed with breast cancer in Canada.
Increasing Breast Cancer Incidences
According to Canadian Cancer Society, 28,600 Canadian women were diagnosed with breast cancer. This represents 25% of all new cancer cases in women in 2022.
Growing Technological Advancements
In 2022, Abemaciclib (Verzenios) was approved by the National Institute for Health and Care Excellence (NICE) to treat some people with breast cancer that has a high-risk of returning.
Research and Development
Growing Demand for Personalized Medicine
The growing demand for personalized medicine has a significant influence on the growth of the Canada Breast Cancer Therapeutics Market. Personalized medicine aims to provide tailored treatment approaches based on an individual's unique characteristics, including genetic makeup, tumor biology, and other relevant factors. In the context of breast cancer, personalized medicine allows healthcare providers to select treatment options that are more likely to be effective for specific patient subgroups. This demand for personalized treatment drives the development and availability of a wide range of targeted therapies, biomarker-driven therapies, and other personalized medicine interventions. Personalized medicine in breast cancer therapeutics enhances treatment efficacy. By understanding the specific genetic alterations and molecular signatures of a patient's tumor, healthcare providers can select therapies that target these specific abnormalities. This approach improves treatment response rates, reduces treatment resistance, and enhances overall treatment outcomes. The demand for personalized medicine is fueled by the desire for more effective treatments and improved patient outcomes. Personalized medicine approaches in breast cancer treatment help minimize adverse effects by tailoring therapies to individual patients. By considering a patient's genetic profile, biomarker status, and other factors, healthcare providers can identify treatments that are more likely to be well-tolerated and have fewer side effects. This reduction in treatment-related adverse effects leads to improved patient quality of life and satisfaction. Personalized medicine relies on the identification of biomarkers associated with specific tumor characteristics or treatment responses. The growing demand for personalized medicine has spurred research efforts to identify relevant biomarkers in breast cancer. These biomarkers can be used in the development of companion diagnostics, which aid in the selection of appropriate therapies for individual patients. The availability of companion diagnostics enhances treatment decision-making and contributes to market growth. The increasing demand for personalized medicine is closely tied to advancements in genomic sequencing technologies. Next-generation sequencing and other genomic profiling techniques enable comprehensive analysis of a patient's tumor, identifying genetic alterations, mutations, and molecular subtypes. These advancements in genomic sequencing technologies have expanded the scope of personalized medicine in breast cancer treatment and have driven the development of targeted therapies and precision medicine approaches.
Growing Collaboration and Partnerships
Collaboration and partnerships play a vital role in influencing the growth of the Canada Breast Cancer Therapeutics Market. Collaboration among researchers, pharmaceutical companies, academic institutions, and healthcare organizations fosters knowledge sharing, resource pooling, and expertise exchange. These collaborative efforts accelerate the pace of R&D activities, leading to advancements in understanding breast cancer biology, the discovery of new therapeutic targets, and the development of innovative treatment approaches. Collaborative R&D initiatives drive innovation, fuel market growth, and contribute to the expansion of treatment options. Collaborative partnerships enable the sharing of resources, infrastructure, and expertise among different stakeholders in the breast cancer therapeutics market. Pharmaceutical companies often collaborate with academic institutions and research organizations to access specialized expertise, patient cohorts, and facilities for conducting clinical trials and preclinical studies. Such collaborations optimize resource utilization, enhance research capabilities, and expedite the development and commercialization of new therapies. Collaborative partnerships facilitate technology transfer and the commercialization of innovative technologies and therapies. Academic-industry collaborations, for example, allow academic institutions to transfer their research findings and intellectual property to pharmaceutical companies for further development and commercialization. These partnerships expedite the translation of scientific discoveries into clinical applications, leading to the availability of novel therapies in the market. Partnerships can be formed to ensure the availability and affordability of therapies to a larger patient population. Collaborations with healthcare systems, hospitals, and clinics help ensure the seamless integration of new treatments into clinical practice and enhance patient access to innovative therapies.
Government Initiatives and Support
Government initiatives and support play a crucial role in influencing the growth of the Canada Breast Cancer Therapeutics Market. Governments provide significant funding for breast cancer research and development, which fuels innovation in therapeutics. Funding is often allocated to research institutions, academic centers, and pharmaceutical companies to support studies focused on understanding breast cancer biology, discovering new treatment targets, and developing novel therapies. This financial support drives R&D activities, accelerates the development of effective treatments, and contributes to the growth of the market. Government regulatory bodies, such as Health Canada, play a critical role in ensuring the safety and efficacy of breast cancer therapeutics. These agencies provide support and guidance to pharmaceutical companies during the drug development process, facilitating the regulatory approval of new therapies. Government initiatives, such as expedited review processes and fast-track designations, help streamline the approval process for promising breast cancer drugs, allowing quicker access to innovative treatments for patients and stimulating market growth. Governments invest in healthcare infrastructure and support initiatives to improve access to breast cancer care. This includes the establishment of comprehensive cancer centers, the expansion of screening and diagnostic services, and the enhancement of treatment facilities. Government support ensures that patients have timely access to high-quality healthcare services, including the latest advancements in breast cancer therapeutics. Improved infrastructure and access to care contribute to market growth by increasing the demand for and utilization of breast cancer treatments. Governments initiate public awareness and education campaigns to promote breast cancer screening, early detection, and treatment options. These campaigns aim to raise awareness about the importance of early diagnosis, encourage regular screenings, and educate the public about found at treatment modalities. By promoting breast cancer awareness and education, governments help in early detection, leading to timely interventions and improved treatment outcomes. Increased awareness and education contribute to the growth of the market as more individuals seek medical attention and engage in breast cancer care.
Recent Developments
- Piqray, a targeted therapy developed by Novartis, gained approval from Health Canada in June 2019. It is utilized in conjunction with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with a PIK3CA mutation in postmenopausal women and men. Piqray is a selective PI3K inhibitor that specifically targets a common genetic alteration in breast cancer.
- Enhertu, an antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo, obtained Health Canada's approval in November 2020. It is indicated for the treatment of HER2-positive, unresectable, or metastatic breast cancer in patients who have previously received treatment with trastuzumab and a taxane. Enhertu combines the HER2-targeting properties of trastuzumab with a cytotoxic payload, providing a more potent treatment option.
- Trodelvy, an antibody-drug conjugate developed by Immunomedics, received approval from Health Canada in December 2020. It is indicated for the treatment of metastatic triple-negative breast cancer (mTNBC) in patients who have undergone at least two prior therapies for metastatic disease. Trodelvy combines an anti-Trop-2 antibody with a cytotoxic payload, allowing targeted delivery of chemotherapy to cancer cells.
Market Segmentation
Canada Breast Cancer Therapeutics Market can be segmented by therapy, end user, region, and competitive landscape. Based on Therapy, Canada Breast Cancer Therapeutics market can be segmented into Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others. Based on End User, the market can be segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others.
Market Players
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | By Therapy By End User By Region |
| Regional scope | Ontario region; Quebec region; Alberta region; British Columbia region; Saskatchewan and Manitoba region; Rest of Canada |
| Key companies profiled | Novartis Pharmaceuticals Canada Inc, Pfizer Canada Inc, Eli Lilly Canada Inc, Merck & Co Inc, GlaxoSmithKline Inc/Canada, AstraZeneca Canada Inc, Bristol-Myers Squibb Canada Inc, Fresenius Kabi Ltd |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy